Marco Aurelio Gralha de Caneda

Dr. Marco Aurelio Gralha de Caneda


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
JFJefferson Gomes Fernandes
Jefferson Gomes Fernandes
AAAndrea Garcia de Almeida
Andrea Garcia de Almeida
FMFabiana Eloisa Mugnol
Fabiana Eloisa Mugnol
Escalas de comprometimento neurológico são utilizadas na avaliação de novos tratamentos, no acompanhamento da evolução clínica e em decisões terapêuticas. Estudamos a confiabilidade de três escalas: a Escala de Rankin (ER), o Índice de Barthel (IB) e a National Institute of Health Stroke Scale (NIHSS) versadas em português, em 51 indivíduos com acidente vascular cerebral, estimando a concordância entre resultados de diferentes examinadores. Utilizamos os coeficientes de concordância Kappa e Coeficiente de Correlação Intraclasse. A ER teve coeficientes moderados, substanciais ou excelentes. No IB estes foram substanciais ou excelentes nos totais e nos itens, assim como quando foi estratificado em agrupamentos prognósticos e funcionais. A NIHSS apresentou coeficientes excelentes nos totais, substanciais nos itens e moderados e excelentes nas estratificações em grupos de pontos e de itens afins. Estes resultados indicam que as versões em português da ER, o IB e a NIHSS apresentam adequada confiabilidade.

1 June 2018 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
DCDaissy Liliana Mora Cuervo
Daissy Liliana Mora Cuervo
NMNathércia Estevam Marinho
Nathércia Estevam Marinho
MVMaria Cecília A. de Vecino
Maria Cecília A. de Vecino
Cognitive Impairment (CI) is a common and distressing problem in Multiple Sclerosis (MS). Its identification is complicated and sometimes omitted in the routine evaluation by neurologists. The BICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) is a promising tool to overcome this difficulty. However, there is some concern regarding the subjectivity in scoring of the BVMT-R (Brief Visuospatial Memory Test - Revised), one of its components. Objective: To evaluate the reliability of the BVMT-R in a sample of Brazilian MS patients, with the measure being administered and scored by neurologists. Methods: BICAMS was applied to seventy subjects comprising forty patients diagnosed with MS and thirty healthy controls. In the MS patients group, the coefficients of agreement between three different raters, using the same protocols, and the internal consistency of the BVMT-R were assessed. Also, the coefficients of correlation of the BVMT-R with the other tests of the BICAMS, CVLT II (California Verbal Learning Test II) and SDMT (Symbol Digit Modalities Test), and their respective effect sizes were calculated. Results: the BVMT-R presented a moderate inter-rater coefficient of agreement (k=0.62), an excellent Intraclass Correlation Coefficient (ICC=0.85), and high internal consistency (α=0.92). The correlation between the BVMT-R and CVLT II was moderate (ρ=0.36; p<0.025), but strong with the SDMT (ρ=0.60; p<0.01), with a large effect size. Conclusion: The BVMT-R is a reliable instrument for assessing CI in patients with MS, having a significant association with information processing speed, an aspect which should be considered when evaluating its score.

1 December 2016 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
MVMaria Cecília A. de Vecino
Maria Cecília A. de Vecino
Multiple sclerosis (MS) may present with a cognitive impairment as disabling as the physical disabilities. Therefore, routine cognitive evaluation is pivotal. Valid and reliable neuropsychological tests are essential in follow-up and to define future therapeutic interventions. Objectives To investigate the correlation between the disabilities of MS patients and their cognitive impairment assessed by the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Methods Forty patients with definitive diagnoses of MS were selected. The correlation coefficient (r) between the Expanded Disability Status Scale (EDSS) and the neuropsychological tests of BICAMS were calculated. Results The correlation was clinically substantial and significant with r = 0.55 (p < 0.01) in the Symbol Digit Modalities Test (SDMT), 0.54 (p < 0.01) in the Brief Visuospacial Memory Test (BVMT) and 0.40 (p < 0.05) in the California Verbal Learning Test (CVLT). Conclusion BICAMS has easy and satisfactory application and evaluation for routine visits and presents a significant correlation with the EDSS. Its use may be indicated for screening and monitoring of cognitive impairment in patients with MS.

1 January 2023 in Radiologia Brasileira
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
MRMarjana Reis Lima Rizzo
Marjana Reis Lima Rizzo
GFGabriela Furlin
Gabriela Furlin
AKAbraão Kupske
Abraão Kupske
BVBruna Bressan Valentini
Bruna Bressan Valentini
MVMaria Cecilia Aragon de Vecino
Maria Cecilia Aragon de Vecino
Objective: To assess the reliability of phase-sensitive inversion recovery (PSIR) magnetic resonance imaging (MRI) and its accuracy for determining the topography of demyelinating cortical lesions in patients with multiple sclerosis (MS). Materials and Methods: This was a cross-sectional study conducted at a tertiary referral center for MS and other demyelinating disorders. We assessed the agreement among three raters for the detection and topographic classification of cortical lesions on fluid-attenuated inversion recovery (FLAIR) and PSIR sequences in patients with MS. Results: We recruited 71 patients with MS. The PSIR sequences detected 50% more lesions than did the FLAIR sequences. For detecting cortical lesions, the level of interrater agreement was satisfactory, with a mean free-response kappa (κFR) coefficient of 0.60, whereas the mean κFR for the topographic reclassification of the lesions was 0.57. On PSIR sequences, the raters reclassified 366 lesions (20% of the lesions detected on FLAIR sequences), with excellent interrater agreement. There was a significant correlation between the total number of lesions detected on PSIR sequences and the Expanded Disability Status Scale score (ρ = 0.35; p < 0.001). Conclusion: It seems that PSIR sequences perform better than do FLAIR sequences, with clinically satisfactory interrater agreement, for the detection and topographic classification of cortical lesions. In our sample of patients with MS, the PSIR MRI findings were significantly associated with the disability status, which could influence decisions regarding the treatment of such patients.

3 September 2024 in International Journal of MS Care
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
CSCamila Batista Oliveira Silva
Camila Batista Oliveira Silva
MVMaria Cecília Aragon de Vecino
Maria Cecília Aragon de Vecino
CE INFORMATION: ACTIVITY AVAILABLE ONLINE: To access the article and evaluation online, go to https://www.highmarksce.com/mscare. TARGET AUDIENCE: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, and other health care providers involved in the management of patients with multiple sclerosis (MS). LEARNING OBJECTIVES: Recognize the importance of comorbidities in the progression of disability in patients with MS. Apply evidence-based clinical strategies for managing comorbidities in patients with MS to improve clinical outcomes. ACCREDITATION: In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. This activity was planned by and for the health care team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. PHYSICIANS: The CMSC designates this journal-based activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSES: The CMSC designates this enduring material for 0.5 contact hour of nursing continuing professional development (NCPD) (none in the area of pharmacology). DISCLOSURES: It is the policy of the Consortium of Multiple Sclerosis Centers to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. For this activity, all relevant disclosures have been mitigated. Francois Bethoux, MD, editor in chief of the International Journal of MS Care (IJMSC), has served as physician planner for this activity. He has disclosed no relevant financial relationships. Alissa Mary Willis, MD, associate editor of IJMSC, has disclosed no relevant financial relationships. Authors Marco Aurélio Gralha de Caneda, MD, MSc, Camila Batista de Oliveira Silva, PhD, and Maria Cecília Aragon de Vecino, MD, have disclosed no relevant financial relationships. The staff at IJMSC, CMSC, and Intellisphere, LLC, who are in a position to influence content, have disclosed no relevant financial relationships. Laurie Scudder, DNP, NP, CMSC continuing education director, has served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships. METHOD OF PARTICIPATION: Release Date: September 1, 2024; Valid for Credit through: September 1, 2025 To receive CE credit, participants must: (1) Review the continuing education information, including learning objectives and author disclosures.(2) Study the educational content.(3) Complete the evaluation, which is available at https://www. highmarksce.com/mscare. Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity. DISCLOSURE OF UNLABELED USE: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC and Intellisphere, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Intellisphere, LLC. DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

1 August 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMarco Aurelio Gralha de Caneda
Marco Aurelio Gralha de Caneda
CSCamila B. Oliveira Silva
Camila B. Oliveira Silva
MLMarjana Reis Lima
Marjana Reis Lima
MVMaria Cecília Vecino
Maria Cecília Vecino
Address for correspondence: Marco Caneda (email: mcaneda@terra.com.br). Abstract Background: Cognitive impairment (CI) is common in multiple sclerosis (MS); it can have disabling consequences on quality of life, and it is often prioritized among MS patients. Its causes are multifactorial. An association between cortical injury and CI has been consistently demonstrated. Furthermore, clinical factors, such as comorbidities, seem to contribute to CI onset; however, few studies have examined their impact on MS cognition. Objective: To evaluate the association between comorbidities and CI in MS. Methods: Patients with MS underwent brain MRI scans, a neuropsychological (NP) assessment, and were screened for the presence of comorbidities. Cortical lesions (CLs) were identified by phase-sensitive inversion recovery (PSIR) MRI sequences. The NP assessment was performed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), with z-scores calculated based on Brazilian normative values. The clinical data and results of the patients without comorbidities (C-) and of those with comorbidities (C+) were compared. The association between CLs, comorbidities, and CI was assessed by a multivariable logistic regression (MLR) analysis. Results: We included 48 individuals: 45.8% were C- and 54.2%, C+. The C+ group was older (48.5 versus 41 years; p = 0.02) and contained more individuals with CI (p = 0.009). The C- group had a higher number of CLs (5±5 versus 2.5±3.2; p = 0.04), but not a higher number of individuals with CL (p = 0.31), and scored better than the C+ group in the SDMT (55.1±16 versus 45.6±21; p = 0.04) and BVMT (24.4±5.9 versus 21.1±7.4; p = 0.05). The MLR analysis identified only comorbidities as significant (p = 0.018) for CI (B = 2.06; OR = 7.85; 95%CI: 1.41–43.4; p = 0.02). Conclusion: Comorbidities increase the chances of developing 0CI. The association of the CL load with CI seems to depend on its interaction with cofactors. Strategies to optimize comorbidities management in MS are warranted. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil